ATE270328T1 - Transgene mäuse, die den leukämie inhibierungsfaktor exprimieren können - Google Patents

Transgene mäuse, die den leukämie inhibierungsfaktor exprimieren können

Info

Publication number
ATE270328T1
ATE270328T1 AT97921444T AT97921444T ATE270328T1 AT E270328 T1 ATE270328 T1 AT E270328T1 AT 97921444 T AT97921444 T AT 97921444T AT 97921444 T AT97921444 T AT 97921444T AT E270328 T1 ATE270328 T1 AT E270328T1
Authority
AT
Austria
Prior art keywords
transgenic mice
pituitary
inhibition factor
disorders
leukemia inhibition
Prior art date
Application number
AT97921444T
Other languages
English (en)
Inventor
Shlomo Melmed
Sadanori Akita
Carol Readhead
Original Assignee
Cedars Sinai Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cedars Sinai Medical Center filed Critical Cedars Sinai Medical Center
Application granted granted Critical
Publication of ATE270328T1 publication Critical patent/ATE270328T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5415—Leukaemia inhibitory factor [LIF]
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Environmental Sciences (AREA)
  • Biomedical Technology (AREA)
  • Animal Husbandry (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Eye Examination Apparatus (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT97921444T 1996-05-09 1997-04-29 Transgene mäuse, die den leukämie inhibierungsfaktor exprimieren können ATE270328T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/647,401 US5824838A (en) 1996-05-09 1996-05-09 Transgenic mouse model for pituitary disorders associated with LIF overexpression and/or GH underexpression, and its use for testing therapeutic drugs for the conditions
PCT/US1997/007177 WO1997042312A1 (en) 1996-05-09 1997-04-29 Transgenic mammals capable of expressing leukemia inhibitory factor

Publications (1)

Publication Number Publication Date
ATE270328T1 true ATE270328T1 (de) 2004-07-15

Family

ID=24596845

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97921444T ATE270328T1 (de) 1996-05-09 1997-04-29 Transgene mäuse, die den leukämie inhibierungsfaktor exprimieren können

Country Status (9)

Country Link
US (1) US5824838A (de)
EP (1) EP0914419B1 (de)
JP (1) JP2000509606A (de)
AT (1) ATE270328T1 (de)
DE (1) DE69729730T2 (de)
DK (1) DK0914419T3 (de)
ES (1) ES2219764T3 (de)
PT (1) PT914419E (de)
WO (1) WO1997042312A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPP053197A0 (en) * 1997-11-26 1997-12-18 Amrad Operations Pty. Limited Compositions
AU744333B2 (en) * 1997-11-26 2002-02-21 Amrad Operations Pty. Limited Compositions of leukaemia inhibitory factor
EP1094831A4 (de) 1998-07-06 2004-11-03 Us Gov Health & Human Serv Zusammensetzungen und verfahren zur (in vitro) fertilisation
US6541244B1 (en) * 1999-06-07 2003-04-01 Cedars-Sinai Medical Center Suppressor of cytokine signaling (SOCS)-3 promoter and methods for its use in genetic therapy in humans
RU2002112751A (ru) 1999-11-12 2004-02-27 Файброджен, Инк. (Us) Рекомбинантные желатины
EP3224381B1 (de) 2014-11-25 2019-09-04 The Brigham and Women's Hospital, Inc. Verfahren zur identifizierung von personen mit einer prädisposition für eine kardiometabolische krankheit oder davon betroffenen personen
WO2016085876A1 (en) 2014-11-25 2016-06-02 The Broad Institute Inc. Clonal haematopoiesis
EP3337923B2 (de) 2015-09-21 2023-01-04 Modern Meadow, Inc. Faserverstärkte gewebeverbundwerkstoffe
JP7109882B2 (ja) 2016-02-15 2022-08-01 モダン メドウ，インコーポレイテッド コラーゲンフィブリルを含むバイオファブリケーテッド材料を作製するための方法
CA3008850A1 (en) 2017-06-29 2018-12-29 Modern Meadow, Inc. Yeast strains and methods for producing collagen
AU2018253595A1 (en) 2017-11-13 2019-05-30 Modern Meadow, Inc. Biofabricated leather articles having zonal properties
AU2020209847B2 (en) 2019-01-17 2024-10-17 Modern Meadow, Inc. Layered collagen materials and methods of making the same
US20220372511A1 (en) * 2019-06-14 2022-11-24 The Regents Of The University Of California Dna construct for targeting therapeutic molecules to diseased tissue by immune cells
EP4143258A4 (de) 2020-05-01 2024-05-22 Modern Meadow, Inc. Proteinpolyurethanlegierungen und schichtmaterialien damit

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4736866B1 (en) * 1984-06-22 1988-04-12 Transgenic non-human mammals
PT87133B (pt) * 1987-04-02 1992-07-31 Amrad Corp Ltd Metodo de purificacao do factor inibidor da leucemia (lif) e de composicoes farmaceuticas contendo polipeptidos com actividade do lif
DE3854823T2 (de) * 1987-05-01 1996-05-23 Stratagene Inc Mutagenesetest durch Verwendung von nicht menschlichen Lebewesen, die Test-DNS-Sequenzen enthalten
US5175385A (en) * 1987-09-03 1992-12-29 Ohio University/Edison Animal Biotechnolgy Center Virus-resistant transgenic mice
US5175384A (en) * 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5215904A (en) * 1989-01-27 1993-06-01 Wisconsin Alumni Research Foundation Method for producing a recombinant mammal in vivo
US5175383A (en) * 1989-02-17 1992-12-29 President And Fellows Of Harvard College Animal model for benign prostatic disease
US5223610A (en) * 1990-05-18 1993-06-29 The Scripps Research Institute Cholera toxin gene regulated by growth hormone promoter

Also Published As

Publication number Publication date
JP2000509606A (ja) 2000-08-02
DK0914419T3 (da) 2004-09-06
EP0914419A1 (de) 1999-05-12
US5824838A (en) 1998-10-20
DE69729730D1 (de) 2004-08-05
DE69729730T2 (de) 2005-07-07
WO1997042312A1 (en) 1997-11-13
PT914419E (pt) 2004-10-29
EP0914419B1 (de) 2004-06-30
ES2219764T3 (es) 2004-12-01

Similar Documents

Publication Publication Date Title
DE69729730D1 (de) Transgene mäuse, die den leukämie inhibierungsfaktor exprimieren können
DK1049767T3 (da) En transgen kanin, der udtrykker et funktionelt humant lipoprotein(A)
DE69109560D1 (de) Fungizide Zusammensetzung zur Behandlung von Saatgut.
DE60129799D1 (de) Verfahren zur steigerung des haarwuchses durch wnt polypeptid
ATE229076T1 (de) Cis elemente des ölkörperproteins als regulationische signale
DE69426206D1 (de) Verbindungen mit wachstumshormonfreisetzenden eigenschaften
ATE57690T1 (de) Pyrazolin mit insektizidischer aktivitaet.
DE69427650D1 (de) Verbindungen mit wachstumshormon-freisetzenden eigenschaften
BRPI0409634A (pt) ligantes de receptores de canabinóides e utilização destes
DE3870508D1 (de) Zusammensetzung zur behandlung des haares.
DE60133271D1 (de) Behandlung von knorpelerkrankungen
ATE540108T1 (de) Familie gh 61 polypeptiden
DE69328025D1 (de) Dorsalgewebe beeinflussender faktor und zusammensetzungen
DK1011723T3 (da) 88KDA tumorgen vækstfaktor og antagonister
ATE372118T1 (de) Die verwendung von rosiglitazon zur behandlung von psychiatrischen erkrankungen.
ES2150901T3 (es) Antagonistas de hormonas del crecimiento.
ATE312919T1 (de) Schmerz signalisierende moleküle
ATE142431T1 (de) Tierfutter zur leistungssteigerung
ATE406438T1 (de) Menschliches homolog aus der familie der metalloproteasen
ATE550345T1 (de) Sfrp, mit sfrp-interagierende peptidmotive sowie verwendungsverfahren
DE59206628D1 (en) Expression signalpeptid-freier staphylokinasen
DE69939586D1 (de) Inhibitoren für die gefässneubildung
DE60119347D1 (de) Verwendung von chimäres il6-il6r in huntingtonskrankheit
DE60124093D1 (de) S-methyl-dihydro-ziprasidon zur Behandlung von Augenerkrankungen.
ATE381324T1 (de) Verwendung von mecamylamine zur behandlung von neuropsychiatrischen krankheiten die auf nicotin ansprechen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0914419

Country of ref document: EP

REN Ceased due to non-payment of the annual fee